These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 12843888

  • 1. [In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter].
    Blondin C, Cholley B, Haeffner-Cavaillon N, Goldschmidt P.
    J Fr Ophtalmol; 2003 Apr; 26(4):328-36. PubMed ID: 12843888
    [Abstract] [Full Text] [Related]

  • 2. Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model.
    Pauly A, Brasnu E, Riancho L, Brignole-Baudouin F, Baudouin C.
    Mol Vis; 2011 Mar 16; 17():745-55. PubMed ID: 21437201
    [Abstract] [Full Text] [Related]

  • 3. Effects of non-steroidal antiallergic eyedrops on the complement-mediated histamine release from human cells.
    Goldschmidt P, Couturier C, Haeffner-Cavaillon N, Kazatchkine M, Herman D.
    Ocul Immunol Inflamm; 1997 Mar 16; 5(1):11-7. PubMed ID: 9145688
    [Abstract] [Full Text] [Related]

  • 4. In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells.
    Guzman-Aranguez A, Calvo P, Ropero I, Pintor J.
    J Ocul Pharmacol Ther; 2014 Nov 16; 30(9):790-8. PubMed ID: 25100331
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the conjunctival toxicity of topical ocular antiallergic agents.
    Lee JS, Lee JE, Kim N, Oum BS.
    J Ocul Pharmacol Ther; 2008 Dec 16; 24(6):557-62. PubMed ID: 19049267
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS.
    Acta Ophthalmol; 2009 Aug 16; 87(5):549-54. PubMed ID: 18631332
    [Abstract] [Full Text] [Related]

  • 7. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
    Mortemousque B, Bourcier T, Khairallah M, Messaoud R, Brignole-Baudouin F, Renault D, Rebika H, Brémond-Gignac D, Ketotifen Study Group.
    J Fr Ophtalmol; 2014 Jan 16; 37(1):1-8. PubMed ID: 24388379
    [Abstract] [Full Text] [Related]

  • 8. Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
    Sanchis-Merino ME, Montero JA, Ruiz-Moreno JM, Rodriguez AE, Pastor S.
    Exp Eye Res; 2008 May 16; 86(5):791-7. PubMed ID: 18378229
    [Abstract] [Full Text] [Related]

  • 9. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study.
    Figus M, Fogagnolo P, Lazzeri S, Capizzi F, Romagnoli M, Canovetti A, Iester M, Ferreras A, Rossetti L, Nardi M.
    Eur J Ophthalmol; 2010 May 16; 20(5):811-8. PubMed ID: 20383847
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC.
    Clin Ther; 2000 Jul 16; 22(7):826-33. PubMed ID: 10945509
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine.
    Lytinas M, Kempuraj D, Huang M, Kandere K, Boucher W, Letourneau R, Jeudy S, Fitzgerald K, Spear K, Athanasiou A, Theoharides TC.
    Allergy Asthma Proc; 2002 Jul 16; 23(1):45-51. PubMed ID: 11894734
    [Abstract] [Full Text] [Related]

  • 16. In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system.
    Blondin C, Hamard P, Cholley B, Haeffner-Cavaillon N, Baudouin C.
    Curr Eye Res; 2003 Oct 16; 27(4):253-9. PubMed ID: 14562177
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
    Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM.
    J Pharmacol Exp Ther; 1996 Sep 16; 278(3):1252-61. PubMed ID: 8819509
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.
    Leonardi A, Zafirakis P.
    Curr Med Res Opin; 2004 Aug 16; 20(8):1167-73. PubMed ID: 15324519
    [Abstract] [Full Text] [Related]

  • 19. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells.
    Kempuraj D, Huang M, Kandere K, Boucher W, Letourneau R, Jeudy S, Fitzgerald K, Spear K, Athanasiou A, Theoharides TC.
    Ann Allergy Asthma Immunol; 2002 May 16; 88(5):501-6. PubMed ID: 12027072
    [Abstract] [Full Text] [Related]

  • 20. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.
    Denis D, Bloch-Michel E, Verin P, Sebastiani A, Tazartes M, Helleboid L, Di Giovanni A, Lecorvec M.
    Br J Ophthalmol; 1998 Oct 16; 82(10):1135-8. PubMed ID: 9924299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.